XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 184 filers reported holding XENON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 2.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,776,320 | -30.1% | 52,000 | -21.2% | 0.16% | -41.8% |
| Q2 2023 | $2,541,000 | +69.6% | 66,000 | +73.7% | 0.28% | +31.2% |
| Q4 2022 | $1,498,340 | -57.1% | 38,000 | -60.7% | 0.22% | -54.7% |
| Q3 2022 | $3,494,000 | +53.1% | 96,800 | +29.1% | 0.48% | +33.4% |
| Q2 2022 | $2,282,000 | -60.7% | 75,000 | -60.5% | 0.36% | -52.5% |
| Q1 2022 | $5,802,000 | -51.0% | 189,797 | -49.9% | 0.75% | -36.8% |
| Q4 2021 | $11,840,000 | +259.2% | 378,997 | +75.7% | 1.18% | +130.5% |
| Q3 2021 | $3,296,000 | -24.2% | 215,697 | -7.7% | 0.51% | -23.2% |
| Q2 2021 | $4,351,000 | -65.7% | 233,697 | -67.0% | 0.67% | -70.7% |
| Q1 2021 | $12,675,000 | +47.7% | 708,117 | +26.9% | 2.28% | +101.6% |
| Q4 2020 | $8,584,000 | +55.0% | 558,117 | +11.6% | 1.13% | -61.4% |
| Q3 2020 | $5,538,000 | +76.0% | 500,264 | +99.4% | 2.94% | +63.7% |
| Q2 2020 | $3,146,000 | +1997.3% | 250,897 | +1796.7% | 1.79% | +925.1% |
| Q1 2020 | $150,000 | -92.9% | 13,228 | -91.8% | 0.18% | -91.4% |
| Q4 2019 | $2,118,000 | – | 161,600 | – | 2.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |